By Fineline Cube Guilin Golden-Horse Innovation Investment Co., Ltd., a wholly owned subsidiary of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766), officially signed an Intent Agreement for Merger and Acquisition with 8PLUS1 Pharma to acquire a controlling stake in the Guilin‑based innovative biopharmaceutical company, the companies announced.
Deal Overview
| Item | Detail |
|---|---|
| Acquirer | Guilin Golden‑Horse Innovation Investment Co., Ltd. (wholly owned subsidiary of Tonghua Golden‑Horse Pharmaceutical, SHE: 000766) |
| Target | 8PLUS1 Pharma |
| Transaction | Intent Agreement for Merger and Acquisition |
| Objective | Acquisition of a controlling stake in 8PLUS1 Pharma |
| Signing Date | 6 Aug 2026 |
| Target Location | Guilin Economic Development Zone, China |
Target Profile – 8PLUS1 Pharma
- Positioning: Domestic innovative biopharmaceutical enterprise focused on first‑in‑class drug discovery
- Therapeutic Focus: Over a decade of deep involvement across three major chronic disease sectors:
- Neurology
- Cardiovascular diseases
- Metabolic diseases
- Intellectual Property: Holds 23 drug development patents
- Clinical Assets: Maintains 3 Class 1 innovative drug clinical trial approvals (INDs)
Pipeline Characteristics
| Attribute | Detail |
|---|---|
| Differentiation | High differentiation across R&D pipeline |
| Unmet Need | Targets substantial unmet clinical demand |
| Global Potential | Pipeline features global first‑in‑class potential |
Strategic Rationale & Market Impact
- Innovation Acquisition: For Tonghua Golden‑Horse (SHE: 000766), acquiring a controlling stake in 8PLUS1 Pharma offers direct access to a differentiated first‑in‑class pipeline across high‑prevalence chronic disease areas.
- Chronic Disease Scale: Neurology, cardiovascular and metabolic diseases represent some of the largest and fastest‑growing therapeutic markets globally, driven by aging populations and rising chronic disease prevalence in China.
- Asset Depth: 23 patents and three Class 1 INDs provide a tangible R&D foundation, giving the acquirer near‑term clinical catalysts alongside longer‑term discovery optionality.
- Regional Synergy: 8PLUS1 Pharma’s base in the Guilin Economic Development Zone positions the deal as a local biopharma consolidation play with policy and ecosystem support.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the contemplated acquisition, integration plans, and the future development of 8PLUS1 Pharma’s pipeline. Actual results may differ due to risks including final transaction terms, regulatory approvals, and clinical outcomes.-Fineline Info & Tech